## Highlights of This Issue 1511

### EDITORIAL

**1513**

**A Message from the Editor-in-Chief**
Michael B. Kastan

### REVIEW

**1514**

**Reovirus: A Targeted Therapeutic—Progress And Potential**
Radhashree Maitra, Mohammad H. Ghalib, and Sanjay Goel

### ANGIOGENESIS, METASTASIS, AND THE CELLULAR MICROENVIRONMENT

**1526**

**Genomic (In)stability of the Breast Tumor Microenvironment**
Seth Rummel, Allyson L. Valente, Jennifer L. Kane, Craig D. Shriver, and Rachel E. Ellsworth

**1532**

**Targeting Tumor Cell Invasion and Dissemination In Vivo by an Aptamer That Inhibits Urokinase-type Plasminogen Activator through a Novel Multifunctional Mechanism**
Kenneth A. Botkjaer, Elena I. Deryugina, Daniel M. Dupont, Henrik Gårdsvo, Erin M. Bekes, Catherine K. Thuesen, Zhou Chen, Michael Ploug, James P. Quigley, and Peter A. Andreassen

**1544**

**MUC1 Drives c-Met–Dependent Migration and Scattering**
Teresa M. Horm, Benjamin G. Biller, Derrick M. Broka, Jeanne M. Louderbough, and Joyce A. Schroeder

**1555**

**PRSS3/Mesotrypsin Is a Therapeutic Target for Metastatic Prostate Cancer**
Alexandra Hockla, Erin Miller, Moh'd A. Salameh, John A. Copland, Derek C. Radisky, and Evette S. Radisky

### CELL CYCLE, CELL DEATH, AND SENESCENCE

**1567**

**The Role of Bel-2L in Synergistic Induction of Apoptosis by Mapatumumab and Oxaliplatin in Combination with Hyperthermia on Human Colon Cancer**
Xinxin Song, Seog-Young Kim, and Yong J. Lee

### DNA DAMAGE AND CELLULAR STRESS RESPONSES

**1580**

**Alkylation Sensitivity Screens Reveal a Conserved Cross-species Functionome**
David Svilar, Madhu Dyavaiah, Ashley R. Brown, Jiang-bo Tang, Jianfeng Li, Peter R. McDonald, Tong Ying Shun, Andrea Braganza, Xiao-hong Wang, Salony Maniar, Claudette M. St Croix, John S. Lazo, Ian F. Pollack, Thomas J. Begley, and Robert W. Sobol

### SIGNALING AND REGULATION

**1597**

**Expression of Wnt3 Activates Wnt/β-Catenin Pathway and Promotes EMT-like Phenotype in Trastuzumab-Resistant HER2-Overexpressing Breast Cancer Cells**
Yanyuan Wu, Charles Ginther, Jurí Kim, Nicole Mosher, Seyung Chung, Dennis Slamon, and Jaydutt V. Vadgama

**1607**

**Analysis of mRNA Profiles after MEK1/2 Inhibition in Human Pancreatic Cancer Cell Lines Reveals Pathways Involved in Drug Sensitivity**
Stephan Gysin, Jesse Paquette, and Martin McMahon

**1620**

**Acknowledgment to Reviewers**
ABOUT THE COVER

Temozolomide is the primary chemotherapy used in the treatment of glioblastoma, but resistance contributes to poor prognosis. A temozolomide/siRNA synthetic lethal screen in a chemotherapy-resistant glioblastoma derived cell line identified many novel genes, including several involved in the response to reactive oxygen species (ROS). Comparison to alkylation screens conducted in *E. coli* and *S. cerevisiae* suggests that alkylation resistance mechanisms are evolutionarily conserved. Using fluorescence-based microscopy, it was found that high-dose temozolomide treatment increases ROS formation in glioma cells, as detected with the superoxide indicator dihydroethidium (DHE). For details, see article by Svilar et al. on page 1580.
Molecular Cancer Research

10 (12)


Updated version
Access the most recent version of this article at:
http://mcr.aacrjournals.org/content/10/12

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://mcr.aacrjournals.org/content/10/12.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.